Scinai Immunotherapeutics Ltd.

𝐖𝐞 𝐚𝐫𝐞 𝐭𝐡𝐫𝐢𝐥𝐥𝐞𝐝 𝐭𝐨 𝐚𝐧𝐧𝐨𝐮𝐧𝐜𝐞 Scinai Immunotherapeutics Ltd. 𝐐𝟑 𝟐𝟎𝟐𝟒 𝐟𝐢𝐧𝐚𝐧𝐜𝐢𝐚𝐥 𝐫𝐞𝐬𝐮𝐥𝐭𝐬, 𝐬𝐡𝐨𝐰𝐜𝐚𝐬𝐢𝐧𝐠 𝐚 𝐬𝐭𝐫𝐞𝐧𝐠𝐭𝐡𝐞𝐧𝐞𝐝 𝐟𝐢𝐧𝐚𝐧𝐜𝐢𝐚𝐥 𝐩𝐨𝐬𝐢𝐭𝐢𝐨𝐧! 📍 A key highlight is the conversion of a €26.6 million loan from the European Investment Bank (EIB) into equity, 𝐭𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐢𝐧𝐠 𝐨𝐮𝐫 𝐬𝐡𝐚𝐫𝐞𝐡𝐨𝐥𝐝𝐞𝐫 𝐞𝐪𝐮𝐢𝐭𝐲 𝐟𝐫𝐨𝐦 𝐚 𝐧𝐞𝐠𝐚𝐭𝐢𝐯𝐞 $𝟕.𝟑 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐚𝐬 𝐨𝐟 𝐉𝐮𝐧𝐞 𝟑𝟎, 𝟐𝟎𝟐𝟒, 𝐭𝐨 𝐚 𝐩𝐨𝐬𝐢𝐭𝐢𝐯𝐞 $𝟏𝟎 𝐦𝐢𝐥𝐥𝐢𝐨𝐧. This strategic move significantly enhances our financial stability and growth prospects. 𝐁̲𝐮̲𝐬̲𝐢̲𝐧̲𝐞̲𝐬̲𝐬̲ ̲𝐔̲𝐧̲𝐢̲𝐭̲𝐬̲ ̲𝐇̲𝐢̲𝐠̲𝐡̲𝐥̲𝐢̲𝐠̲𝐡̲𝐭̲𝐬̲:̲ 👉 𝑂𝑢𝑟 𝐶𝐷𝑀𝑂 𝑏𝑢𝑠𝑖𝑛𝑒𝑠𝑠 𝑢𝑛𝑖𝑡 𝑟𝑒𝑐𝑜𝑟𝑑𝑒𝑑 𝑟𝑒𝑣𝑒𝑛𝑢𝑒𝑠 𝑓𝑜𝑟 𝑡ℎ𝑒 𝑓𝑖𝑟𝑠𝑡 𝑡𝑖𝑚𝑒, 𝑚𝑎𝑟𝑘𝑖𝑛𝑔 𝑎 𝑠𝑜𝑙𝑖𝑑 𝑒𝑎𝑟𝑙𝑦 𝑝𝑒𝑟𝑓𝑜𝑟𝑚𝑎𝑛𝑐𝑒. While 2024 revenues are expected to remain moderate, we are negotiating attractive contracts with several companies. Additionally, we received a $575K non-refundable grant from the Israeli Innovation Authority (IIA), with another grant application for $267K pending. As demand for specialized CDMO services grows, we are positioning ourselves as a key partner for early-stage biotech companies. 👉 𝑂𝑢𝑟 𝑅&𝐷 𝐵𝑢𝑠𝑖𝑛𝑒𝑠𝑠 𝑢𝑛𝑖𝑡 𝑐𝑜𝑛𝑡𝑖𝑛𝑢𝑒𝑑 𝑡𝑜 𝑎𝑑𝑣𝑎𝑛𝑐𝑒 𝑜𝑢𝑟 𝑖𝑛𝑛𝑜𝑣𝑎𝑡𝑖𝑣𝑒 𝑝𝑖𝑝𝑒𝑙𝑖𝑛𝑒, 𝑝𝑢𝑏𝑙𝑖𝑠ℎ𝑖𝑛𝑔 𝑝𝑟𝑜𝑚𝑖𝑠𝑖𝑛𝑔 𝑝𝑟𝑒-𝑐𝑙𝑖𝑛𝑖𝑐𝑎𝑙 𝑝𝑟𝑜𝑜𝑓 𝑜𝑓 𝑐𝑜𝑛𝑐𝑒𝑝𝑡 𝑟𝑒𝑠𝑢𝑙𝑡𝑠 𝑎𝑛𝑑 𝑟𝑒𝑐𝑒𝑖𝑣𝑖𝑛𝑔 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑟𝑒𝑔𝑢𝑙𝑎𝑡𝑜𝑟𝑦 𝑓𝑒𝑒𝑑𝑏𝑎𝑐𝑘 from the Paul Ehrlich Institute for our planned clinical trials in plaque psoriasis. We are actively pursuing partnership opportunities for our anti-IL-17A/F nanoAb for plaque psoriasis and our additional, novel pipeline nanoAbs, all of this while exploring strategic licensing agreements to expand our pipeline. These positive developments in both our financial positioning and operational growth demonstrate our commitment to strengthening our foundation and delivering value to our shareholders and partners. 👉👉 For more details, view the full Q3 report: https://lnkd.in/diFQEVEk #FinancialResults #Q3 #Growth #Innovation #TeamSuccess #Biotech #BioPharma #NASDAQ  Amir Reichman

𝐓𝐫𝐚𝐧𝐬𝐢𝐭𝐢𝐨𝐧𝐢𝐧𝐠 𝐚 𝐦𝐨𝐥𝐞𝐜𝐮𝐥𝐞 𝐟𝐫𝐨𝐦 𝐚𝐧 𝐚𝐜𝐚𝐝𝐞𝐦𝐢𝐜 𝐬𝐞𝐭𝐭𝐢𝐧𝐠 𝐭𝐨 𝐭𝐡𝐞 𝐜𝐨𝐦𝐦𝐞𝐫𝐜𝐢𝐚𝐥 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐫𝐞𝐪𝐮𝐢𝐫𝐞𝐬 𝐚 𝐬𝐢𝐠𝐧𝐢𝐟𝐢𝐜𝐚𝐧𝐭 𝐦𝐢𝐧𝐝𝐬𝐞𝐭 𝐬𝐡𝐢𝐟𝐭. 📍 While academic research often emphasizes exploration, the pharmaceutical industry prioritizes practical outcomes and scalability. 📍 Successful drug development demands agility, precision, and speed at every stage. It’s crucial to think ahead and plan for large-scale production from the very beginning, even when working on small-scale processes. 👉 For example: 𝐸𝑛𝑠𝑢𝑟𝑒 𝑡ℎ𝑎𝑡 𝑡ℎ𝑒 𝑟𝑎𝑤 𝑚𝑎𝑡𝑒𝑟𝑖𝑎𝑙𝑠 𝑢𝑠𝑒𝑑 𝑑𝑢𝑟𝑖𝑛𝑔 𝑒𝑎𝑟𝑙𝑦 𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑚𝑒𝑛𝑡 𝑎𝑟𝑒 𝑛𝑜𝑡 𝑜𝑛𝑙𝑦 𝑎𝑣𝑎𝑖𝑙𝑎𝑏𝑙𝑒 𝑏𝑢𝑡 𝑎𝑙𝑠𝑜 𝑚𝑒𝑒𝑡 𝑡ℎ𝑒 𝑟𝑒𝑔𝑢𝑙𝑎𝑡𝑜𝑟𝑦 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑠 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑓𝑜𝑟 𝑦𝑜𝑢𝑟 𝑓𝑖𝑛𝑎𝑙 𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑜𝑛 𝑠𝑡𝑎𝑔𝑒. 𝑂𝑣𝑒𝑟𝑙𝑜𝑜𝑘𝑖𝑛𝑔 𝑡ℎ𝑖𝑠 𝑐𝑎𝑛 𝑙𝑒𝑎𝑑 𝑡𝑜 𝑐𝑜𝑠𝑡𝑙𝑦 𝑑𝑒𝑙𝑎𝑦𝑠 𝑎𝑛𝑑 𝑠𝑒𝑡𝑏𝑎𝑐𝑘𝑠 𝑙𝑎𝑡𝑒𝑟 𝑖𝑛 𝑡ℎ𝑒 𝑝𝑟𝑜𝑐𝑒𝑠𝑠. 👇Check out below some valuable insights and recommendations from Dr. Dalit Fischer, CTO of Scinai Immunotherapeutics Ltd.! 👉👉 Explore our eBook, ‘A User’s Guide to Drug Development ‘, for more practical insights and expert guidance. Discover actionable strategies for navigating the complexities of bringing a drug to market. >> https://lnkd.in/dT98zPad #DrugDevelopment #PharmaInsights #Innovation #CDMO #MoleculeSelection #ExpertInsights #Biotech Amir Reichman Elad Mark Tamar Ben-Yedidia Dalit Fischer

𝐓𝐫𝐚𝐧𝐬𝐢𝐭𝐢𝐨𝐧𝐢𝐧𝐠 𝐚 𝐦𝐨𝐥𝐞𝐜𝐮𝐥𝐞 𝐟𝐫𝐨𝐦 𝐚𝐧 𝐚𝐜𝐚𝐝𝐞𝐦𝐢𝐜 𝐬𝐞𝐭𝐭𝐢𝐧𝐠 𝐭𝐨 𝐭𝐡𝐞 𝐜𝐨𝐦𝐦𝐞𝐫𝐜𝐢𝐚𝐥 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐫𝐞𝐪𝐮𝐢𝐫𝐞𝐬 𝐚 𝐬𝐢𝐠𝐧𝐢𝐟𝐢𝐜𝐚𝐧𝐭 𝐦𝐢𝐧𝐝𝐬𝐞𝐭 𝐬𝐡𝐢𝐟𝐭. 📍 While academic research often emphasizes exploration, the pharmaceutical industry prioritizes practical outcomes and scalability. 📍 Successful drug development demands agility, precision, and speed at every stage. It’s crucial to think ahead and plan for large-scale production from the very beginning, even when working on small-scale processes. 👉 For example: 𝐸𝑛𝑠𝑢𝑟𝑒 𝑡ℎ𝑎𝑡 𝑡ℎ𝑒 𝑟𝑎𝑤 𝑚𝑎𝑡𝑒𝑟𝑖𝑎𝑙𝑠 𝑢𝑠𝑒𝑑 𝑑𝑢𝑟𝑖𝑛𝑔 𝑒𝑎𝑟𝑙𝑦 𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑚𝑒𝑛𝑡 𝑎𝑟𝑒 𝑛𝑜𝑡 𝑜𝑛𝑙𝑦 𝑎𝑣𝑎𝑖𝑙𝑎𝑏𝑙𝑒 𝑏𝑢𝑡 𝑎𝑙𝑠𝑜 𝑚𝑒𝑒𝑡 𝑡ℎ𝑒 𝑟𝑒𝑔𝑢𝑙𝑎𝑡𝑜𝑟𝑦 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑠 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑓𝑜𝑟 𝑦𝑜𝑢𝑟 𝑓𝑖𝑛𝑎𝑙 𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑜𝑛 𝑠𝑡𝑎𝑔𝑒. 𝑂𝑣𝑒𝑟𝑙𝑜𝑜𝑘𝑖𝑛𝑔 𝑡ℎ𝑖𝑠 𝑐𝑎𝑛 𝑙𝑒𝑎𝑑 𝑡𝑜 𝑐𝑜𝑠𝑡𝑙𝑦 𝑑𝑒𝑙𝑎𝑦𝑠 𝑎𝑛𝑑 𝑠𝑒𝑡𝑏𝑎𝑐𝑘𝑠 𝑙𝑎𝑡𝑒𝑟 𝑖𝑛 𝑡ℎ𝑒 𝑝𝑟𝑜𝑐𝑒𝑠𝑠. 👇Check out below some valuable insights and recommendations from Dr. Dalit Fischer, CTO of Scinai Immunotherapeutics Ltd.! 👉👉 Explore our eBook, ‘A User’s Guide to Drug Development ‘, for more practical insights and expert guidance. Discover actionable strategies for navigating the complexities of bringing a drug to market. >> https://lnkd.in/dT98zPad #DrugDevelopment #PharmaInsights #Innovation #CDMO #MoleculeSelection #ExpertInsights #Biotech Amir Reichman Elad Mark Tamar Ben-Yedidia Dalit Fischer

#MeetTheExpert In our "Meet the Expert" series we are proud to spotlight Zohar Gadri, MSc, who heads the Process Development and Optimization efforts at Scinai Immunotherapeutics Ltd.. Working with Scinai for 13 years, Zohar specializes in protein purification, transitioning processes from laboratory settings to GMP-compliant production. 𝐙𝐨𝐡𝐚𝐫 𝐬𝐡𝐚𝐫𝐞𝐬 𝐡𝐢𝐬 𝐩𝐞𝐫𝐬𝐩𝐞𝐜𝐭𝐢𝐯𝐞 𝐨𝐧 𝐭𝐡𝐞 𝐢𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐜𝐞 𝐨𝐟 𝐦𝐢𝐜𝐫𝐨𝐨𝐫𝐠𝐚𝐧𝐢𝐬𝐦 𝐬𝐞𝐥𝐞𝐜𝐭𝐢𝐨𝐧 𝐢𝐧 𝐛𝐢𝐨𝐩𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧:  "𝐶ℎ𝑜𝑜𝑠𝑖𝑛𝑔 𝑡ℎ𝑒 𝑟𝑖𝑔ℎ𝑡 𝑚𝑖𝑐𝑟𝑜𝑜𝑟𝑔𝑎𝑛𝑖𝑠𝑚 𝑓𝑜𝑟 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑜𝑛 𝑖𝑠 𝑛𝑜𝑡 𝑗𝑢𝑠𝑡 𝑎𝑏𝑜𝑢𝑡 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦; 𝑖𝑡'𝑠 𝑎𝑏𝑜𝑢𝑡 𝑏𝑢𝑖𝑙𝑑𝑖𝑛𝑔 𝑎 𝑓𝑜𝑢𝑛𝑑𝑎𝑡𝑖𝑜𝑛 𝑓𝑜𝑟 𝑠𝑐𝑎𝑙𝑎𝑏𝑙𝑒 𝑎𝑛𝑑 𝑠𝑢𝑠𝑡𝑎𝑖𝑛𝑎𝑏𝑙𝑒 𝑚𝑎𝑛𝑢𝑓𝑎𝑐𝑡𝑢𝑟𝑖𝑛𝑔 𝑝𝑟𝑜𝑐𝑒𝑠𝑠𝑒𝑠," he explains. 𝐇𝐢𝐬 𝐤𝐞𝐲 𝐜𝐨𝐧𝐬𝐢𝐝𝐞𝐫𝐚𝐭𝐢𝐨𝐧𝐬 𝐢𝐧 𝐦𝐢𝐜𝐫𝐨𝐨𝐫𝐠𝐚𝐧𝐢𝐬𝐦 𝐬𝐞𝐥𝐞𝐜𝐭𝐢𝐨𝐧 𝐟𝐨𝐫 𝐩𝐫𝐨𝐭𝐞𝐢𝐧 𝐩𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧: - Substrate Utilization: "Selecting a microorganism that efficiently utilizes substrates not only maximizes production but also reduces costs." - Genetic Stability: "A stable genetic makeup ensures consistent output and quality over time, crucial for regulatory compliance." - Production Efficacy: "Optimal microorganisms should demonstrate high production efficacy under varying operational conditions, enhancing scalability." He also emphasizes the strategic approach needed in biopharmaceutical manufacturing, "𝐼𝑡’𝑠 𝑐𝑟𝑢𝑐𝑖𝑎𝑙 𝑡𝑜 𝑐𝑜𝑛𝑠𝑖𝑑𝑒𝑟 𝑡ℎ𝑒 𝑓𝑢𝑙𝑙 𝑙𝑖𝑓𝑒𝑐𝑦𝑐𝑙𝑒 𝑜𝑓 𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑜𝑛 𝑓𝑟𝑜𝑚 𝑡ℎ𝑒 𝑜𝑢𝑡𝑠𝑒𝑡. 𝑂𝑝𝑡𝑖𝑚𝑖𝑧𝑖𝑛𝑔 𝑚𝑖𝑐𝑟𝑜𝑏𝑖𝑎𝑙 ℎ𝑜𝑠𝑡𝑠 𝑓𝑜𝑟 𝑏𝑒𝑡𝑡𝑒𝑟 𝑦𝑖𝑒𝑙𝑑 𝑎𝑛𝑑 𝑠𝑡𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑐𝑎𝑛 𝑠𝑖𝑔𝑛𝑖𝑓𝑖𝑐𝑎𝑛𝑡𝑙𝑦 𝑒𝑛ℎ𝑎𝑛𝑐𝑒 𝑡ℎ𝑒 𝑑𝑜𝑤𝑛𝑠𝑡𝑟𝑒𝑎𝑚 𝑝𝑟𝑜𝑐𝑒𝑠𝑠𝑖𝑛𝑔 𝑎𝑛𝑑 𝑜𝑣𝑒𝑟𝑎𝑙𝑙 𝑝𝑟𝑜𝑑𝑢𝑐𝑡 𝑒𝑓𝑓𝑖𝑐𝑎𝑐𝑦." 𝐙𝐨𝐡𝐚𝐫'𝐬 𝐞𝐱𝐩𝐞𝐫𝐭𝐢𝐬𝐞 𝐞𝐧𝐬𝐮𝐫𝐞𝐬 𝐭𝐡𝐚𝐭 𝐒𝐜𝐢𝐧𝐚𝐢'𝐬 𝐩𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧 𝐩𝐫𝐨𝐜𝐞𝐬𝐬𝐞𝐬 𝐚𝐫𝐞 𝐫𝐨𝐛𝐮𝐬𝐭 𝐚𝐧𝐝 𝐜𝐚𝐩𝐚𝐛𝐥𝐞 𝐨𝐟 𝐦𝐞𝐞𝐭𝐢𝐧𝐠 𝐭𝐡𝐞 𝐜𝐨𝐦𝐩𝐥𝐞𝐱 𝐝𝐞𝐦𝐚𝐧𝐝𝐬 𝐨𝐟 𝐦𝐨𝐝𝐞𝐫𝐧 𝐝𝐫𝐮𝐠 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭. 𝐇𝐢𝐬 𝐰𝐨𝐫𝐤 𝐬𝐮𝐩𝐩𝐨𝐫𝐭𝐬 𝐨𝐮𝐫 𝐜𝐨𝐦𝐦𝐢𝐭𝐦𝐞𝐧𝐭 𝐭𝐨 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐞𝐱𝐜𝐞𝐥𝐥𝐞𝐧𝐜𝐞 𝐢𝐧 𝐜𝐫𝐞𝐚𝐭𝐢𝐧𝐠 𝐞𝐟𝐟𝐞𝐜𝐭𝐢𝐯𝐞 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭𝐬. Stay tuned for more expert insights from the Scinai team! #Biopharmaceuticals #ProteinProduction #Biotechnology #ProcessDevelopment #InnovationInBiotech #DrugDevelopment #ExpertInsights #ProcessOptimization #GMPProduction #Scalability #MicroorganismSelection #Bioproduction #BiotechExcellence

Live from #BioEurope2024! Scinai Immunotherapeutics Ltd. leadership team is excited to open #BioEurope2024 and invite pharma partners, investors and biotech innovators to visit us at booth #150. We look forward to meeting: - Prospective clients seeking our comprehensive, end-to-end CDMO services. - Pharma partners in the I&I field interested in co-development or in-licensing opportunities for our innovative NanoAbs. - Dermatology partners interested in our targeted treatment for mild to moderate plaque psoriasis—a locally administered, “Botox-like” approach for psoriatic patients. Join us on the journey to #biopharma innovation. #CDMO #BioServices #sdAb #plaquepsoriasis #dermatology #partnership #innovation Amir Reichman Dalit Fischer

Happy Diwali to all our partners, colleagues and followers who celebrate this wonderful holiday of light. Wishing you endless joy, prosperity, and warmth to your home and family this Diwali. Best wishes from all of us at Scinai Immunotherapeutics Ltd. #HappyDiwali

𝐖𝐞 𝐚𝐫𝐞 𝐩𝐥𝐞𝐚𝐬𝐞𝐝 𝐭𝐨 𝐚𝐧𝐧𝐨𝐮𝐧𝐜𝐞 𝐭𝐡𝐚𝐭 𝐒𝐜𝐢𝐧𝐚𝐢 𝐈𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐋𝐭𝐝. (𝐍𝐚𝐬𝐝𝐚𝐪: 𝐒𝐂𝐍𝐈) 𝐰𝐢𝐥𝐥 𝐛𝐞 𝐬𝐡𝐨𝐰𝐜𝐚𝐬𝐢𝐧𝐠 𝐢𝐭𝐬 𝐜𝐆𝐌𝐏 𝐛𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬 𝐂𝐃𝐌𝐎 𝐬𝐞𝐫𝐯𝐢𝐜𝐞𝐬 𝐚𝐧𝐝 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐯𝐞 𝐢𝐧𝐟𝐥𝐚𝐦𝐦𝐚𝐭𝐢𝐨𝐧 & 𝐢𝐦𝐦𝐮𝐧𝐨𝐥𝐨𝐠𝐲 (𝐈&𝐈) 𝐩𝐢𝐩𝐞𝐥𝐢𝐧𝐞 𝐚𝐭 𝐁𝐈𝐎-𝐄𝐮𝐫𝐨𝐩𝐞 𝟐𝟎𝟐𝟒, 𝐡𝐞𝐥𝐝 𝐢𝐧 𝐒𝐭𝐨𝐜𝐤𝐡𝐨𝐥𝐦 𝐟𝐫𝐨𝐦 𝐍𝐨𝐯𝐞𝐦𝐛𝐞𝐫 𝟒-𝟔. Scinai’s CEO, Amir Reichman, and CTO, Dr. Dalit Fischer, will be available to meet with: - Prospective clients seeking our comprehensive, end-to-end CDMO services. - Pharma partners in the I&I field interested in co-development or in-licensing opportunities for our innovative NanoAbs. - Dermatology partners interested in our targeted treatment for mild to moderate plaque psoriasis—a localized, “Botox-like” approach for psoriatic patients. - Institutional and private investors exploring SCNI’s value proposition. 𝑇𝑜 𝑠𝑐ℎ𝑒𝑑𝑢𝑙𝑒 𝑎 𝑚𝑒𝑒𝑡𝑖𝑛𝑔, 𝑝𝑙𝑒𝑎𝑠𝑒 𝑐𝑜𝑛𝑛𝑒𝑐𝑡 𝑤𝑖𝑡ℎ 𝑢𝑠 𝑡ℎ𝑟𝑜𝑢𝑔ℎ 𝑡ℎ𝑒 𝑐𝑜𝑛𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑝𝑎𝑟𝑡𝑛𝑒𝑟𝑖𝑛𝑔 𝑝𝑙𝑎𝑡𝑓𝑜𝑟𝑚 𝑜𝑟 𝑒𝑚𝑎𝑖𝑙 𝑏𝑑@𝑠𝑐𝑖𝑛𝑎𝑖.𝑐𝑜𝑚. 𝑂𝑢𝑟 𝑡𝑒𝑎𝑚 𝑤𝑖𝑙𝑙 𝑎𝑙𝑠𝑜 𝑏𝑒 𝑎𝑣𝑎𝑖𝑙𝑎𝑏𝑙𝑒 𝑎𝑡 𝑒𝑥ℎ𝑖𝑏𝑖𝑡𝑜𝑟 𝑏𝑜𝑜𝑡ℎ #150 𝑡ℎ𝑟𝑜𝑢𝑔ℎ𝑜𝑢𝑡 𝑡ℎ𝑒 𝑐𝑜𝑛𝑓𝑒𝑟𝑒𝑛𝑐𝑒. #BIOEurope #Scinai #CDMO #Immunology #Dermatology #Biotech #Pharma https://lnkd.in/d4BkJR83

#Psoriasis affects 125 million people worldwide. It’s more than a skin condition—it can impact every aspect of life, bringing both physical discomfort and emotional strain. 🤝 This #WorldPsoriasisDay, we’re stepping up to support those living with plaque psoriasis, which accounts for 80-90% of cases. 📍 At Scinai Immunotherapeutics Ltd., we are dedicated to transforming psoriasis care. Our drug development program focuses on a targeted therapy specifically for mild to moderate plaque psoriasis. Leveraging single-domain antibodies (sdAbs), including our anti-IL-17A/F sdAb, we are advancing a locally administered biologic that combines high potency and convenience with a safer profile than current treatments. 👉 Join us in raising awareness and supporting those affected by psoriasis. Together, we can make a difference for millions. 🌐 Visit Scinai.com to learn more #InnovativeResearch #Healthcare #Biotechnology #Dermatology #WorldPsoriasisDay24

🌟 #BioEurope is just around the corner, and we invite #pharma partners to connect with us and explore our cutting-edge product pipeline! 👉 Join us at booth #150 to explore Scinai Immunotherapeutics Ltd. #VHH #sdAb pipeline of Alpaca-derived nanobodies exclusively licensed from Max Planck Institute and the University Medical Center Göttingen. 📍Our pipeline targets diseases with significant unmet needs, including #psoriasis and #asthma, with a focus on underserved patient populations. 🎯 Our nanobodies offer unique properties, enabling targeted biologic delivery and expanding access to those previously limited by cost or side effects. 📍 With pre-clinical proof-of-concept studies completed and a psoriasis program entering clinical trials in 2025, we’re seeking partners to help bring these innovations forward. 🤝Let’s connect at #BioEurope to explore collaboration opportunities. Scinai offers advanced labs and #cGMP manufacturing capabilities in Israel, making us a strong and self-sufficient partner. 👉👉 Schedule a meeting via the BioEurope Partnering One platform or drop us an email at bd@scinai.com We look forward to meeting you at #BioEurope24 Amir Reichman Dalit Fischer

𝑾𝒉𝒂𝒕 𝒐𝒑𝒑𝒐𝒓𝒕𝒖𝒏𝒊𝒕𝒊𝒆𝒔 𝒅𝒐 𝑽𝑯𝑯 𝒔𝒅𝑨𝒃𝒔 (𝒔𝒊𝒏𝒈𝒍𝒆-𝒅𝒐𝒎𝒂𝒊𝒏 𝒂𝒏𝒕𝒊𝒃𝒐𝒅𝒊𝒆𝒔) 𝒑𝒓𝒆𝒔𝒆𝒏𝒕 𝒇𝒐𝒓 𝒕𝒓𝒆𝒂𝒕𝒊𝒏𝒈 𝒎𝒊𝒍𝒅 𝒕𝒐 𝒎𝒐𝒅𝒆𝒓𝒂𝒕𝒆 𝒑𝒍𝒂𝒒𝒖𝒆 𝒑𝒔𝒐𝒓𝒊𝒂𝒔𝒊𝒔? 𝑯𝒐𝒘 𝒅𝒐𝒆𝒔 𝑺𝒄𝒊𝒏𝒂𝒊 𝑰𝒎𝒎𝒖𝒏𝒐𝒕𝒉𝒆𝒓𝒂𝒑𝒆𝒖𝒕𝒊𝒄𝒔 𝑳𝒕𝒅.'𝒔 𝒊𝒏𝒕𝒓𝒂𝒍𝒆𝒔𝒊𝒐𝒏𝒂𝒍 𝑨𝒏𝒕𝒊-𝑰𝑳17 𝑨/𝑭 𝒔𝒅𝑨𝑩 𝒘𝒐𝒓𝒌, 𝒂𝒏𝒅 𝒘𝒉𝒚 𝒊𝒔 𝒊𝒕 𝒖𝒏𝒊𝒒𝒖𝒆𝒍𝒚 𝒑𝒐𝒔𝒊𝒕𝒊𝒐𝒏𝒆𝒅 𝒕𝒐 𝒎𝒆𝒆𝒕 𝒕𝒉𝒆 𝒔𝒊𝒈𝒏𝒊𝒇𝒊𝒄𝒂𝒏𝒕 𝒖𝒏𝒎𝒆𝒕 𝒏𝒆𝒆𝒅𝒔 𝒊𝒏 𝒕𝒉𝒊𝒔 𝒎𝒂𝒓𝒌𝒆𝒕? Hear our distinguished expert panel address these questions, during the panel discussion: "𝐏𝐥𝐚𝐪𝐮𝐞 𝐏𝐬𝐨𝐫𝐢𝐚𝐬𝐢𝐬. 𝐓𝐡𝐞 𝐔𝐧𝐦𝐞𝐭 𝐍𝐞𝐞𝐝 𝐚𝐧𝐝 𝐈𝐧𝐭𝐫𝐚𝐥𝐞𝐬𝐢𝐨𝐧𝐚𝐥 𝐈𝐧𝐣𝐞𝐜𝐭𝐢𝐨𝐧𝐬 𝐨𝐟 𝐀𝐧𝐭𝐢-𝐈𝐋𝟏𝟕 𝐀/𝐅 𝐕𝐇𝐇 𝐚𝐧𝐭𝐢𝐛𝐨𝐝𝐢𝐞𝐬 𝐚𝐬 𝐚 𝐩𝐨𝐭𝐞𝐧𝐭𝐢𝐚𝐥 𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧". -Prof. Michael Schön – Director, Department of Dermatology and Venereology, University Medical Center Goettingen -Prof. Matthias Dobbelstein – Max Planck Institute Fellow, Professor and Department Head, University Medical Center Göttingen (UMG) - Amir Reichman – CEO, Scinai Immunotherapeutics Ltd. - Dr. Tamar Ben-Yedidia – CSO, Scinai Immunotherapeutics Ltd. View the full webinar recording to discover insights into the plaque psoriasis landscape, the current treatment options, the unmet need; and the potential of VHH sdAbs to transform psoriasis care. https://lnkd.in/dW8BH3KE #PsoriasisTreatment #VHHsdAbs #Immunotherapy #Biotechnology #Dermatology #ScinaiImmunotherapeutics #InnovativeHealthcare